Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis

CONCLUSION: Switching from adalimumab originator to SB5 for NIU does not result in clinically significant differences in treatment efficacy and safety.PMID:38194436 | DOI:10.1080/09273948.2023.2295544
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Authors: Source Type: research